When a family member is diagnosed with Alzheimer’s or another form of dementia, the memantine vs donepezil question comes up fast. These are the two most commonly prescribed drug classes for the disease in the United States, and they work in completely different ways. Most families want a straight answer: which one actually helps more?
The honest answer is, it depends on what stage of the disease your loved one is in, and what symptoms you’re hoping to address. Neither drug stops dementia. Neither reverses it. But used at the right time, in the right patient, they can buy meaningful months, sometimes longer, of better function.
Here’s how the two compare in real-world practice, what the evidence actually shows, and what to expect if your prescriber recommends one, the other, or both together. For background, the National Institute on Aging maintains a useful overview of FDA-approved dementia treatments.
How Memantine and Donepezil Actually Work
Donepezil (brand name Aricept) is a cholinesterase inhibitor. It blocks the enzyme that breaks down acetylcholine, a neurotransmitter involved in memory and learning. Alzheimer’s patients lose acetylcholine-producing neurons early in the disease, so propping up what’s left tends to help with cognition, attention, and day-to-day function.
Memantine (brand name Namenda) is a different beast. It’s an NMDA receptor antagonist. In Alzheimer’s, glutamate signaling goes haywire, which damages neurons over time. Memantine dampens that excess glutamate activity without shutting it off entirely. Think of it less as a memory booster and more as a brake on further damage.
That mechanistic difference is the whole reason the memantine vs donepezil debate exists. They’re not really competing. They’re addressing different problems in the same disease.
Which Stage of Dementia Each Drug Targets
This is where most of the confusion comes from, and it’s the single most important thing to get right.
- Donepezil is FDA-approved for mild, moderate, and severe Alzheimer’s. It’s typically the first drug started after diagnosis.
- Memantine is FDA-approved only for moderate to severe Alzheimer’s. Starting it in mild disease isn’t supported by trials and generally isn’t recommended.
So for a newly diagnosed patient with mild symptoms, donepezil usually wins by default. The memantine vs donepezil choice becomes more interesting as the disease progresses to moderate stages, when memantine becomes an option, either as a switch or, more often, as an add-on.
Combination therapy, donepezil plus memantine, is common in moderate-to-severe disease. A 2012 NEJM trial found that patients on combination therapy generally did better on cognitive and functional measures than those on donepezil alone, though effect sizes were modest. If you want a deeper look at how donepezil is dosed and what to expect in the early months, we cover that in our guide on donepezil for Alzheimer’s.
Side Effects: Where They Really Differ
This is often the deciding factor in practice. The two drugs have very different tolerability profiles.
Donepezil side effects come from boosting acetylcholine everywhere, not just in the brain:
- Nausea, diarrhea, loss of appetite (common in the first 4 to 6 weeks)
- Vivid dreams or nightmares
- Muscle cramps
- Slow heart rate, sometimes enough to cause fainting
- Weight loss, which matters in frail elderly patients
About one in five patients on donepezil stop it within the first few months because of GI side effects.
Memantine is generally better tolerated. The main complaints are:
- Dizziness
- Headache
- Confusion (paradoxically, in a small subset)
- Constipation
For families dealing with a patient who’s already underweight or has cardiac conduction issues, memantine’s gentler profile is often what tips the scale. The Mayo Clinic’s memantine overview lays out the side-effect list in more detail.
What the Evidence Says About Effectiveness
Both drugs produce modest improvements in cognition and daily function. Neither is a home run. In trial data, donepezil typically improves cognitive scores by 2 to 3 points on the ADAS-cog scale over six months. Memantine produces similar small improvements in moderate-to-severe disease.
Family members usually notice changes in things like:
- Better recognition of familiar people
- Slightly improved attention during conversations
- Less agitation in late afternoon (more often with memantine)
- Some preservation of basic self-care skills
What they don’t see: a return to baseline. If you’re hoping for the person you remember from two years ago, neither drug will deliver that. What they can do is slow the slope of decline, sometimes noticeably.
This pattern of "modest but real" benefit shows up across a lot of chronic-disease drug comparisons. We see something similar in our writeup on melatonin versus trazodone for sleep, where the right drug depends entirely on the patient’s specific situation.
Cost and Practical Considerations
Both drugs are available as generics, which has made the memantine vs donepezil cost question much less painful than it used to be. Generic donepezil tablets typically run a few dollars a month with insurance. Generic memantine is similarly affordable, though the extended-release version (Namenda XR) costs more.
You can compare prices on generic donepezil and memantine at edrugstore.com if your current pharmacy quote seems high.
A few practical notes prescribers think about:
- Donepezil is once daily, usually at bedtime, which is easy for caregivers to manage.
- Memantine is typically twice daily as immediate-release, or once daily as XR.
- Both need slow dose titration to minimize side effects. Your prescriber will determine the right starting dose and titration schedule.
- Neither should be stopped abruptly without medical guidance, since rapid decline can follow.
The Bottom Line on Memantine vs Donepezil
The memantine vs donepezil decision usually isn’t either/or. For mild Alzheimer’s, donepezil first. As the disease progresses to moderate or severe stages, memantine often gets added on rather than substituted. Patients who can’t tolerate donepezil’s GI effects sometimes do well on memantine alone, even in moderate disease.
What matters most is matching the drug to the patient: their stage of disease, their other medical conditions, their tolerance for side effects, and what the family is hoping to gain. Talk to your prescriber or a edrugstore.com pharmacist about whether memantine, donepezil, or the combination makes sense for your situation, and revisit that conversation as the disease evolves.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- National Institute on Aging, How Alzheimer’s Disease Is Treated, overview of FDA-approved dementia drugs and treatment goals.
- FDA, Information on Aricept (Donepezil), approved indications and safety information.
- NEJM, Donepezil and Memantine for Moderate-to-Severe Alzheimer’s Disease (2012), landmark trial on combination versus monotherapy.
- Mayo Clinic, Memantine Oral Route, clinical detail on memantine dosing and side effects.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More